PARP1 and familial pancreatic carcinoma: Wang et al. have shown that the treatment of PARP inhibitor pamiparib increases PD-L1 expression in pancreatic cancer cells and the combination of pamiparib and PD-L1 mAb improved therapeutic efficacy when compared to monotherapy [100].